Protected: Vision-sparing targeted phototherapy for uveal melanoma
There is no excerpt because this is a protected post.
Protected: Vision-sparing targeted phototherapy for uveal melanoma Read More »
Uveal Melanoma
Virus-like particle-drug conjugates induce protective, long-lasting adaptive anti-tumor immunity in the absence of specifically targeted tumor antigens
Published in: Cancer Immunology Research Authors: Rhonda C Kines, Cynthia D Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks, John T Schiller Related application note: Vision-sparing targeted phototherapy for uveal melanoma
Modulight Spotlights: LASER-SHARP RESEARCH – April 2021
Modulight Spotlights: LASER-SHARP RESEARCH – April 2021 Dr. Rhonda Kines and the team at Aura Biosciences reported promising results of their VLP (virus-like particle) photosensitizer-conjugate eliciting strong and long-lasting anti-tumor immune responses, as well as potential to combine this agent with immune checkpoint inhibitors for even improved antitumor efficacy. Read original publication Modulight is
Modulight Spotlights: LASER-SHARP RESEARCH – April 2021 Read More »
An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Published in: Molecular Cancer Therapeutics Authors: Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos, and John T. Schiller